Aldevron, LLC entered into an agreement to acquire global exclusive license for Codex® HiCap RNA Polymerase from Codexis, Inc. (NasdaqGS:CDXS) on December 13, 2023. Under the terms of the deal, Aldevron will receive global manufacturing and commercialization rights to the Codex® HiCap RNA Polymerase and Codexis will receive payments for near-term technical milestones, along with commercial milestones and sales-based royalties.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.65 USD | +1.11% | +3.40% | +19.67% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.67% | 258M | |
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+47.02% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |
- Stock Market
- Equities
- CDXS Stock
- News Codexis, Inc.
- Aldevron, LLC entered into an agreement to acquire global exclusive license for Codex® HiCap RNA Polymerase from Codexis, Inc..